V
VIVOSIM LABS, INC.
NASDAQ: VIVS (VivoSim Labs, Inc.)
Last update: 20 hours ago0.283
-0.02 (-5.57%)
| Previous Close | 0.300 |
| Volume | 385,633 |
| Price / Sales | 8.00 |
| Price / Book | 0.540 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,184.31% |
| Diluted EPS (TTM) | -1.70 |
| Quarterly Revenue Growth (YOY) | 75.90% |
| Total Debt/Equity (MRQ) | 8.98% |
| Current Ratio (MRQ) | 3.25 |
| Operating Cash Flow (TTM) | -9.46 M |
| Levered Free Cash Flow (TTM) | -5.03 M |
| Return on Assets (TTM) | -75.10% |
| Return on Equity (TTM) | -35.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | VivoSim Labs, Inc. | - | - |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.00% |
| % Held by Institutions | 6.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fny Investment Advisers, Llc | 30 Jun 2026 | 200 |
| Albion Financial Group /Ut | 30 Jun 2026 | 159 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIALIN TONY SERGE | 0.290 | - | 10,000 | 2,900 |
| Aggregate Net Quantity | 10,000 | |||
| Aggregate Net Value ($) | 2,900 | |||
| Aggregate Avg. Buy ($) | 0.290 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIALIN TONY SERGE | Officer | 31 Aug 2026 | Buy (+) | 10,000 | 0.290 | 2,900 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |